Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...
Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...
Pyxis Oncology, Inc. (PYXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it ...
Pyxis Tankers Inc. (PXS) closed the most recent trading day at $4.05, moving -1.46% from the previous trading session. This change lagged the S&P 500's 0.65% loss on the day. Meanwhile, the Dow gained ...
Any time a business conference producer approaches the day when all the speakers and attendees get on airplanes and fly to the venue, things change fast. A speaker cancels and has to be replaced at ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Pyxis One, a California-based tech startup that aims to revolutionize marketing and consumer intelligence by providing an all-in-one, codeless AI platform, closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results